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Epithelial-mesenchymal transition(EMT)isamultistepprocess in whichcells acquire molecular alterations suchas lossofcell-cell
junctions and restructuring of the cytoskeleton. There is an increasing understanding that this process may promote breast cancer
progression through promotion of invasive and metastatic tumor growth. Recent observations imply that there may be a cross-talk
between EMT and cancer stem cell properties, leading to enhanced tumorigenicity and the capacity to generate heterogeneous
tumor cell populations. Here, we review the experimental and clinical evidence for the involvement of EMT in cancer stem cell
theory, focusing on the common characteristics of this phenomenon.
1.Introduction
Relapse and resultant metastatic spread to distant sites of
malignant neoplasms remain the leading cause of mortality
associated with cancer [1, 2]. The classical metastatic cascade
includes intravasation by cancer cells, their circulation in
the lymph and blood vascular systems, extravasation, and
growth into metastatic foci [3, 4]. However, metastasis is
considered to be an ineﬃcient process, since only very few
cells among the numerous cancercells in the circulation have
the ability to invade and form distant nodules [5]. In the
past decade, two diﬀerent concepts related to solid tumor
progression have emerged and been intensively studied to
explain these complicated phenomena. There is a grow-
ing understanding that epithelial-mesenchymal transition
(EMT) can contribute to invasive and metastatic tumor
growth. This process is considered to ultimately promote
cancercellprogressionthroughthebasementmembraneand
invasion into the surrounding microenvironment, such as
the lymph and blood vascular systems, contributing to intra-
orextravasation[6–8].Ontheotherhand,thereisincreasing
data to support the hypothesis that most tumors include
a minor subpopulation of cells with distinct properties
similar to somatic stem cells, which are referred to as cancer
stem cells (CSCs) or tumor-initiating cells. CSCs have been
reported to have enhanced tumorigenicity, compared with
the majority of tumor cells from the same tumor, and the
capacity to generate heterogeneous tumor cell populations
[9–11]. Initially, these concepts were individually studied;
however, Mani et al. suggested that there may be an
association between EMT and the gain of CSC properties in
breast cancer cells in 2008 [12], and another group reported
that gene expression patterns of CSC-associated pathways
were involved in EMT [13]. Here, we review recent studies
of CSCs and the relationship with EMT and we consider
what implications this correlation may have for our ability
to explain aspects of tumor progression including distant
metastasis.
2. Role of EMT in Tumor Metastasis
EMT was originally deﬁned as a latent embryonic process
causing epithelial cells to lose their epithelial behavior
and acquire the properties of mesenchymal cells [14, 15].2 Journal of Oncology
This is a multistep process in which cells obtain molec-
ular alterations that cause dysfunctional cell-cell adhesive
interactions, loss of cell-cell junctions, and restructuring
of the cytoskeleton; all of which result in the loss of
apical polarity and the acquisition of a more spindle-shaped
morphology [16–21]. This process is an important part
of early development. For example, in vertebrates, this
process facilitates the formation of a three-layered embryo
by gastrulation [22, 23] and the mesenchymal phenotype
allows migration to the proper site for organ formation
[24]. In neoplasia, a comparable process is supposed
to arise on the tumor front, allowing for cellular inva-
sion and eventual metastatic dissemination of cancer cells
[17, 25, 26].
EMT in tumor progression can be induced by several
cytokines and chemokines, including transforming growth
factor-β (TGFβ)[ 27]. An increasing constitutive produc-
tion and release of TGFβ by tumor cells leads to the
activation of the TGFβ signaling pathway in an autocrine
fashion, which results in an EMT state with a highly
invasive and metastatic phenotype [28–30]. As signiﬁcant
evidence of EMT in vivo, recently, Giampieri and colleagues
used elegant intravital imaging studies to visualize either
collective or single-cell migration of cancer cells. They
showed that TGFβ signaling could drive a switch to single-
cell migration without cell-cell attachment and that the
mode of migration determined the way the tumor spread
[31].
Exogenous expression of many developmentally impor-
tant transcription factors is also known to induce EMT.
Transcriptional repression of E-cadherin is mediated by
members of the Snail/Slug family and Twist, and their
critical role in EMT was conﬁrmed by studies of abla-
tion of Snail in vivo [32]. Both Twist and Snail pro-
mote tumor cell metastasis with no apparent stimulation
of primary tumor growth. Snail even attenuates the cell
cycle, rather than promoting proliferation, suggesting that
these EMT regulators are also convincing metastasis genes
[33–35].
Accordingly, activation of these processes in cancer cells
signiﬁcantly increases their metastatic potential, but some
argument still exists as to whether EMT is a suﬃcient
condition for cancer metastasis. Evidence for the role of
EMT is complicated by the fact that at the secondary site
the metastatic cells likely change those cellular phenotype to
show heterogeneity, permitting colonization of the distant
site. Several lines of experimental result have accumulated
that indicate mesenchymal-epithelial transition (MET) may
be important for the latter stages of metastasis, when
cancer cells regenerate complex growth that recapitulate
the histopathological complexity of the primary tumors
from which they arose [36, 37]. Recent publications have
demonstrated that MET is essential for the reprogramming
of ﬁbroblasts to induced pluripotent stem cells [38], suggest-
ing the correlation between the reprogramming process in
some cases and repression of the EMT program. Another
study has shown that CSCs are necessary for homeostasis of
metastaticcellsthatwouldrequirethereversionofEMT[39].
Therefore, in the course of cancer progression, EMT may be
a transient and reversible process and not only EMT but also
pluripotent roles in epithelial plasticity may be essential for
the establishment of cancer metastasis.
3. CancerStemCellTheoryofTumorMetastasis
The hypothesis that the majority of solid tumors contain a
small subpopulation of cells with distinct properties similar
to somatic stem cells is supported by both basic and clinical
studies. This is a not-so-recent hypothesis that began with
the discovery of a cell capable of initiating human acute
myeloid leukemia. The population of cells that possessed the
potential for self-renewal and diﬀerentiation was assumed to
be a leukemia stem cell [40]. In 2003, Al-Hajj and colleagues
for the ﬁrst time isolated a CD44+/CD24
−/low subpopulation
of breast cancer cells and showed that the cells in this
population produced tumors in a xenograft model more
eﬀectively than did the majority population of tumor cells
[9]. CD44+/CD24
−/low cells were subsequently designated
as CSCs, and this discovery has enhanced investigation of
CSCs as the metastatic component of cancer, especially
in breast cancer. Conceptually, CSCs must be engaged in
the metastatic process if they are the only subset of cells
capable of initiating new tumor growth. If that is the case,
metastatic cells in the circulation should have the tumori-
genic capacity necessary to induce tumor initiation at a
distant metastatic site. This hypothesis was partly supported
by reports showing that CD44+/CD24
−/low status of primary
tumor was signiﬁcantly correlated with distant-metastatic-
free survival [41, 42], although the clinical relevance of the
CD44+/CD24
−/low phenotype in primary breast cancer is still
controversial. Furthermore, CD44+/CD24
−/low breast cancer
cells expressed high levels of genes related to metastasis and
induced lung metastasis in vivo [43]. In addition, analysis of
genetic proﬁles conﬁrmed that CD44+ breast cancer cells are
enriched with stem-cell markers and display activated TGFβ
signaling and poor clinical outcomes [44].
The expression of aldehyde dehydrogenase 1 (ALDH1)
has also been shown to be a CSC marker, and CSCs
have been isolated from primary breast cancer using an
ALDEFLUOR assay [45]. A recent study demonstrated that
ALDH1 expression can be an independent prognostic factor
for predicting metastasis in inﬂammatory breast cancer and
that CSCs have the ability to reconstitute the heterogeneity
of the primary tumor at the metastatic site [46]. ALDH1 was
also identiﬁed as a predictor of poor prognosis in lung and
bladder cancer [47, 48].
In the small and large intestine, leucine-rich repeat-
containing G protein-coupled receptor 5 (LGR5) was iden-
tiﬁed as a marker for stem cells [49] and deletion of APC in
LGR5-expressing cells induced their transformation within
days, suggesting that LGR5 might be a limited population of
CSCs [50]. From a clinical point of view, we recently showed
that LGR5 was markedly overexpressed in the majority of
advanced colorectal cancers (CRCs) compared with normal
m u c o s a lt i s s u e[ 51]. This LGR5 expression, which was
variable among CRC cases, correlated signiﬁcantly with
lymph node metastasis, suggesting the involvement of LGR5
in the metastatic process.Journal of Oncology 3
4. Common Characteristics in EMTand
Tumor-InitiatingAbility
4.1. TGFβ Signaling Pathway. Several studies have indicated
t h a tE M Ti n d u c e r sc a nm a k ec a n c e rc e l l sb e c o m em o r e
tumorigenic[7],givingrisetothehypothesisthattumorcells
can transiently acquire stem cell-like properties as a conse-
quence of EMT. Mani and colleagues performed in vitro-
based experiments and reported that the induction of EMT
in human mammary epithelial cells resulted in the acquisi-
tionofmesenchymalmorphologyandtheexpressionofmes-
enchymal markers. This phenotypic EMT change increased
the CD44+/CD24
−/low subpopulation, which exhibited the
properties of stem cells, such as enhanced mammosphere-
forming ability and diﬀerentiation into myoepithelial or
luminal epithelial cells. They also demonstrated that trans-
formed human mammary epithelial cells showed eﬀective
tumor-initiating ability with induction of EMT [12]. In that
report, induction of EMT that resulted in the enrichment
of CSCs was conducted by activation of the TGFβ pathway,
as well as by ectopic expression of the transcription factors
Snail, Slug, and Twist.
Generally, activation of the TGFβ pathway inhibits
tumorigenesis; however, it is also known that the TGFβ
pathway cooperates with other pathways to assist tumorige-
nesis in the malignant state [52, 53]. Genetic signatures that
predict poorer prognosis for primary breast cancer patients
have been examined by comparing the gene expression
proﬁles of CD44+/CD24
−/low cell populations with other
populations[42,44].Followingupontheaboveobservations
on the TGFβ pathway, one of these studies, which performed
SAGE proﬁling of CD44+/CD24
−/low and CD44+/−/CD24+
cell populations from breast cancer tissue, found expression
of TGFβ targets, such as VIMENTINE, CTGF, SERPINE1,
SPARC,andTGFBR2,implyingTGFβpathwaysseemedtobe
activated in these cells. Another recent study also has shown
thatgeneexpressionsignatureofhumanmammaryepithelial
cell line introduced EMT inducers including TGFβ strongly
correlatedwiththesignaturederivedfrombasalBcelllinesof
which subtype is characterized by a stem cell-like expression
proﬁle [54].
To induce complete EMT, TGFβ works together with
the Wnt, Hedgehog, Notch, and Ras signaling pathways,
which are involved in the induction and maintenance of
stem cell niches [55]. The canonical Wnt pathway, known
to be a critical regulator of self-renewal in stem cell niches,
is also implicated in the induction of EMT in cancer and
is constitutively activated in colon, skin, and hematopoietic
cancers [56–58].
In contrast, Tang et al. reported that TGFβ inhibition
increased the size of the CSC population and promoted
tumorigenesis by a mechanism that was independent of
direct eﬀects on proliferation. In that study, which used
transformed human breast epithelial cells, TGFβ stimulation
resulted in the loss of stem cell-like properties such as
ability to form mammospheres [59]. Thus, further studies
are needed to clarify these contradictory results on the
role of TGFβ signaling in the regulation of tumor-initiating
property and EMT.
4.2. Circulating Tumor Cells. Identiﬁcation of detectable
circulating tumor cells (CTCs) in the peripheral blood of
patients with solid tumors has been intensively studied for a
decade, since CTCs may provide proof of principle for early
primary cancer cell metastasis through the vascular network
[60–62]. Several lines of evidence suggest that the ﬁnding
of CTCs in the course of therapy possesses a consistent
prognostic signiﬁcance and is regarded as a predictive tool
for response to treatments in cancer therapy [63, 64].
In this context, a recent study conducted in a cohort
of 226 blood samples from 39 patients revealed that the
majority of CTCs from metastatic breast cancer patients had
EMT and CSC characteristics [65]. In that study, CTCs were
found in 69 of 226 (31%) blood samples taken from patients
with metastatic breast cancer to investigate the expression
of EMT markers (Twist, AKT2, and PI3Kα)a n das t e mc e l l
marker (ALDH1). In the CTC-positive group, 62% were
positive for the EMT markers and 69% for ALDH1, while in
the CTC-negative group the percentages were 7% and 14%,
respectively [65]. CTCs also showed reduced expression of
epithelial-speciﬁc cytokeratins [66]. In disseminated tumor
cells (DTCs), Twist, which is known as an EMT inducer,
was overexpressed and the presence of Twist-positive cells
in the bone marrow prior to chemotherapy has been
signiﬁcantly associated with relapse [67]. These results
indicated that CTCs (or DTCs) might often exhibit char-
acteristics of both EMT and CSCs, emphasizing their role
in the formation of metastases. Therefore, further studies
focused on identifying the features of cancer cells that have
escaped from the primary tumor may allow the discovery
of the critical mechanisms underlying cancer metastasis and
recurrence.
4.3. Chemoresistance. It has been widely observed that many
CSCpopulationsareresistanttochemotherapy.Onepossible
mechanism underlying chemoresistance is thought to arise
from metabolic quiescence, a high level of expression of anti-
apoptotic proteins [68, 69]. Another is the high expression
of ATP-binding cassette (ABC) family genes, such as MDR1
and BCRP1, which could catalyze the eﬄu xo far a n g e
of structurally unrelated anticancer drugs [70–72]. This
property is shared by a subpopulation of normal stem cells
known as “side population” (SP) cells. SP cells have been
detected in several solid tumors, including breast, lung, and
gastrointestinal cancers and have been shown to have the
capacity for tumor initiation and self-renewal [71, 73–75].
Therefore, the identiﬁcation of SP cells by ﬂow cytometry is
a promising method for the extraction of CSC populations
in solid tumors.
Induction of EMT also contributes to the decreased
eﬃcacy of chemotherapy in breast [76], colorectal [77],
and ovarian cancer [78]. Introduction of Twist into breast
cancer cells induces paclitaxel resistance and EMT, as well
as AKT2 expression, which was ampliﬁed in breast cancer
with acquired paclitaxel resistance [76]. A detailed character-
ization of cell systems reveals that mesenchymal derivatives
of nonsmall cell lung cancer cells display an attribute of
resistance to EGFR kinase inhibitor [79]. Creighton and
colleagues reported in 2009 that a gene expression signature4 Journal of Oncology
common to both CD44+/CD24
−/low and mammosphere-
forming cells was found mainly in human breast cancer of
the recently identiﬁed claudin-low molecular subtype, which
is characterized by expression of many EMT-associated
genes. They also demonstrated that residual breast cancer
cell populations after conventional chemotherapy may be
enriched for subpopulations of cells with both CSCs and
mesenchymal features [13]. Consistently, CSCs, isolated
using CD44+/CD24
−/low from human breast cancer, demon-
strated resistance against the chemotherapeutic agents and
the proportion of CD44+/CD24
−/low cells increased in breast
cancerpatientsaftertreatmentwithanticancerdrugs,includ-
ing docetaxel, doxorubicin, and cyclophosphamide [80]. Of
the 1% of cells that survived chemotherapy using paclitaxel
or 5-ﬂuorouracil, 30–35% of them were CD44+/CD24
−/low,
indicating selection of this population.
On the basis of the above relationship between EMT and
CSCs, using two populations of human mammary epithelial
(HMLE)cells—onethathadbeeninducedEMTbyknocking
down of E-cadherin and one which had not—Gupta and
colleagues screened a collection of about 16,000 compounds
to ﬁnd one showing selective toxicity towards the cells that
had undergone EMT [81]. As the result of the screening,
salinomycin was selected for further studies and was also
discovered to suppress the proportion of CSCs that occur
naturally as a subpopulation of breast cancer cells. Pre-
treatment with paclitaxel was found to increase the tumor
initiation ability more than 100 folds compared with pre-
treatment of salinomycin.
These results point to the potential mechanisms of
chemoresistance that allow CSC population increased by
EMT to persistently survive and that may be responsible
for recurrence in the primary or distant site following
cancer treatment by chemotherapy after the majority of the
cancer cells are killed. Taken together with the report by
Mani et al. [12], these studies have led to the possibility
that resistance to chemotherapy may be associated with
the common characteristics of EMT and tumor-initiation
abilities.
5. Conclusion
According to recent ﬁndings in this review, EMT may be a
critical process underlying the subpopulation of cancer cells,
CSCs, that are responsible for tumor initiation at metastatic
sites and for regenerating the tumor after initial tumor
regression by chemotherapy. This hypothesis may provide
insight into current questions about the speciﬁc role of EMT
in tumor metastasis. Therefore, identiﬁcation of CSCs as
speciﬁcally signiﬁcant characteristics of tumor malignancy
facilitated by EMT can help to provide an answer for this
critical issue. Additional studies will be necessary in order to
better establish and increase our understanding.
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